Montelukast Viatris
Leukotriene receptor antagonist for asthma and allergic rhinitis
Montelukast Viatris contains montelukast, a leukotriene receptor antagonist that blocks inflammatory substances called leukotrienes. It is prescribed for the long-term prevention and treatment of asthma in adults and adolescents aged 15 years and older, and for relief of seasonal allergic rhinitis symptoms. This medication is taken as one 10 mg tablet once daily in the evening and is not intended for acute asthma attacks.
Quick Facts
Key Takeaways
- Montelukast Viatris is a once-daily oral tablet that blocks leukotrienes to reduce airway inflammation and bronchoconstriction in asthma.
- It is used as add-on therapy when inhaled corticosteroids alone do not provide adequate asthma control, and also prevents exercise-induced bronchoconstriction.
- The 10 mg film-coated tablet is intended for adults and adolescents aged 15 years and older; different formulations exist for younger patients.
- Important neuropsychiatric side effects (mood changes, depression, suicidal ideation) have been reported — patients should be monitored and seek medical attention if symptoms occur.
- This medication should never be used to treat acute asthma attacks — always keep a rescue bronchodilator inhaler readily available.
What Is Montelukast Viatris and What Is It Used For?
Montelukast Viatris contains the active substance montelukast, which belongs to a class of medications known as leukotriene receptor antagonists (LTRAs). Leukotrienes are potent inflammatory mediators released by mast cells and eosinophils during allergic and inflammatory responses. They cause bronchoconstriction (narrowing of the airways), increased mucus production, and swelling of the airway lining. By selectively blocking the cysteinyl leukotriene type 1 (CysLT1) receptor, montelukast inhibits these effects and helps to keep the airways open.
This medication is prescribed for adults and adolescents aged 15 years and older who have not achieved adequate asthma control with their current inhaled therapy. It serves as an add-on treatment to inhaled corticosteroids (ICS) and can also be used as an alternative to low-dose ICS in patients with mild persistent asthma. According to the Global Initiative for Asthma (GINA) 2024 guidelines, LTRAs are considered a step 2 alternative controller option and may be combined with other asthma therapies at higher treatment steps.
In addition to asthma management, Montelukast Viatris is effective in preventing exercise-induced bronchoconstriction (EIB). For individuals who experience airway narrowing during or after physical activity, montelukast taken regularly can significantly reduce the severity and frequency of these episodes. Clinical trials have demonstrated that montelukast provides protection against EIB within 2 hours of administration and maintains efficacy for up to 24 hours.
Montelukast Viatris can also be used for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) in patients who also have asthma. Seasonal allergic rhinitis is an immune response triggered by airborne allergens such as pollen from trees, grasses, and weeds. Symptoms include nasal congestion, runny nose, sneezing, and itchy, watery eyes. Since leukotrienes contribute to nasal inflammation and congestion, blocking them with montelukast provides symptomatic relief alongside the primary asthma treatment.
Understanding Asthma
Asthma is a chronic respiratory condition characterised by reversible airway obstruction, airway hyperresponsiveness, and underlying inflammation. The World Health Organization (WHO) estimates that approximately 262 million people worldwide are affected by asthma, and it accounts for over 450,000 deaths annually. Key symptoms include recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, often worse at night or in the early morning.
The airways of people with asthma are chronically inflamed and hypersensitive to various triggers including allergens (dust mites, pet dander, pollen), irritants (tobacco smoke, air pollution), cold air, exercise, and respiratory infections. When exposed to these triggers, the smooth muscle surrounding the airways contracts, the lining swells, and excess mucus is produced, collectively leading to airflow limitation and the characteristic symptoms of an asthma attack.
Understanding Seasonal Allergic Rhinitis
Seasonal allergic rhinitis, commonly known as hay fever, is an allergic condition triggered by airborne pollen from trees, grasses, or weeds. The immune system overreacts to these harmless substances, releasing histamine and leukotrienes that cause inflammation of the nasal passages. Typical symptoms include a congested, runny, or itchy nose; repeated sneezing; and watery, swollen, red, and itchy eyes. Seasonal allergic rhinitis affects an estimated 10–30% of the global population and frequently co-exists with asthma, as both conditions share common allergic inflammatory pathways.
What Should You Know Before Taking Montelukast Viatris?
Before starting Montelukast Viatris, it is essential to inform your healthcare provider about your complete medical history, current medications, and any allergies. This medication is not suitable for everyone, and certain conditions or drug combinations require careful evaluation by a physician. Understanding the contraindications, warnings, and precautions helps ensure safe and effective use.
Contraindications
You must not take Montelukast Viatris if you have a known allergy (hypersensitivity) to montelukast or to any of the other ingredients in the tablet. The excipients include microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate, colloidal anhydrous silica, and the film-coating components including indigo carmine aluminium lake (E132) and para-orange aluminium lake (E110). If you have experienced an allergic reaction to any of these substances previously, this medication is contraindicated.
Warnings and Precautions
Neuropsychiatric events including agitation, aggressive behaviour, hostility, anxiety, depression, sleep disturbances, hallucinations, disorientation, suicidal thinking and behaviour have been reported in patients taking montelukast across all age groups. The FDA issued a Boxed Warning (its most prominent safety warning) for montelukast in March 2020 due to these serious neuropsychiatric events. If you or a family member notices any behavioural or mood changes, contact your doctor immediately and discuss whether to discontinue treatment.
Not for acute asthma attacks: Montelukast Viatris is a preventive medication and must not be used to treat acute asthma attacks or status asthmaticus. If an asthma attack occurs, follow the emergency plan prescribed by your doctor. Always carry your rescue bronchodilator inhaler (e.g., salbutamol/albuterol) for acute relief. If you find yourself needing your rescue inhaler more frequently than usual, contact your healthcare provider for a reassessment of your asthma management plan.
Do not stop other asthma medications: Montelukast Viatris is intended as add-on therapy. It should not replace inhaled corticosteroids or other asthma medications prescribed by your doctor. All current asthma medications should be continued unless your physician specifically instructs otherwise. Abrupt discontinuation of corticosteroids, in particular, can lead to serious adrenal insufficiency and asthma exacerbation.
Aspirin sensitivity: If you have aspirin-sensitive asthma, continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while taking montelukast. Although montelukast may reduce airway hypersensitivity over time, it does not provide complete protection against aspirin-induced reactions, and avoidance remains the primary strategy.
Churg–Strauss syndrome: In very rare cases, patients taking montelukast (particularly when oral corticosteroid doses are being reduced) have developed a combination of symptoms including flu-like illness, tingling or numbness in the arms or legs, worsening respiratory symptoms, and/or skin rash. This constellation may indicate eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome), a serious systemic vasculitis. Seek immediate medical attention if you develop these symptoms.
Montelukast Viatris 10 mg film-coated tablets contain para-orange aluminium lake (E110), which may cause allergic reactions in susceptible individuals. This excipient is also known as Sunset Yellow FCF. Patients with known sensitivity to azo dyes should inform their doctor. The tablets also contain less than 1 mmol (23 mg) sodium per tablet, making them essentially sodium-free.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before taking Montelukast Viatris. There is limited clinical data on the use of montelukast during pregnancy. Animal studies have not shown harmful effects on the foetus; however, as with all medications during pregnancy, montelukast should only be used if the potential benefit justifies the potential risk. The European Medicines Agency (EMA) and the British National Formulary (BNF) advise that montelukast can be considered during pregnancy if deemed clinically necessary, particularly when uncontrolled asthma poses a greater risk to both mother and foetus.
It is not known whether montelukast is excreted in human breast milk. Studies in rats have shown that montelukast is secreted in milk. Discuss with your healthcare provider before using this medicine if you are breastfeeding or plan to breastfeed, so they can weigh the benefits of treatment against potential risks to the infant.
Driving and Operating Machinery
Montelukast Viatris is not generally expected to affect your ability to drive or operate machinery. However, individual reactions may vary. Some patients have reported dizziness, drowsiness, and somnolence as side effects. If you experience any of these symptoms, avoid driving or operating heavy machinery until you know how the medication affects you. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness.
Children and Adolescents
Montelukast Viatris 10 mg film-coated tablets are specifically formulated for adults and adolescents aged 15 years and older. This dosage form should not be given to children under 15 years of age. Alternative formulations of montelukast (chewable tablets and granules) are available for paediatric patients in age-appropriate strengths, as determined by the prescribing physician.
How Does Montelukast Viatris Interact with Other Drugs?
Montelukast is primarily metabolised by cytochrome P450 enzymes, mainly CYP3A4 and to a lesser extent CYP2C8 and CYP2C9. Drugs that induce or inhibit these enzymes can alter montelukast plasma levels and potentially affect its therapeutic efficacy or safety profile. Although montelukast has a relatively favourable drug interaction profile compared to many other medications, several important interactions should be considered.
It is crucial to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or might take, including prescription drugs, over-the-counter medicines, herbal products, and dietary supplements. Your healthcare provider can assess whether any dosage adjustments or monitoring are needed.
| Drug | Interaction Type | Effect | Clinical Significance |
|---|---|---|---|
| Phenobarbital | CYP3A4 inducer | Decreases montelukast plasma levels by approximately 40% | Moderate — may reduce efficacy |
| Phenytoin | CYP3A4 inducer | Decreases montelukast plasma levels | Moderate — may reduce efficacy |
| Rifampicin | Potent CYP3A4 inducer | Significantly decreases montelukast plasma levels | Major — avoid combination if possible |
| Gemfibrozil | CYP2C8 inhibitor | Increases montelukast AUC by approximately 4.4-fold | Major — increased risk of side effects |
| Inhaled corticosteroids | Pharmacodynamic | Additive anti-inflammatory effect | Beneficial — commonly used together |
| Short-acting beta-agonists | Pharmacodynamic | Complementary bronchodilation | Beneficial — safe to combine |
Major Interactions
Rifampicin is one of the most potent CYP3A4 enzyme inducers known. Co-administration with montelukast can dramatically reduce montelukast plasma concentrations, potentially rendering the drug ineffective. If you require treatment with rifampicin (commonly used for tuberculosis and certain other infections), your doctor may need to consider alternative asthma treatments or closely monitor your asthma control.
Gemfibrozil, a fibrate used to treat elevated blood lipid levels, is a potent inhibitor of CYP2C8. Studies have shown that co-administration of gemfibrozil with montelukast increases montelukast exposure (AUC) by approximately 4.4-fold. This significant increase may heighten the risk of dose-dependent adverse effects. If both medications are necessary, your doctor will carefully weigh the benefits against risks and may implement enhanced monitoring.
Minor Interactions
Montelukast can generally be used safely alongside most common asthma medications including inhaled corticosteroids (e.g., budesonide, fluticasone), long-acting beta-agonists (LABAs such as salmeterol, formoterol), short-acting beta-agonists (SABAs such as salbutamol/albuterol), and oral antihistamines. Clinical studies have demonstrated no clinically significant pharmacokinetic interactions between montelukast and these commonly co-prescribed agents.
In vitro studies indicate that montelukast is a potent inhibitor of CYP2C8. Therefore, caution is advised when co-administering montelukast with drugs metabolised primarily by CYP2C8, such as paclitaxel, rosiglitazone, and repaglinide. However, in clinical practice, montelukast doses and plasma concentrations are generally low enough that significant CYP2C8 inhibition is unlikely.
What Is the Correct Dosage of Montelukast Viatris?
Always take Montelukast Viatris exactly as your doctor or pharmacist has instructed. Do not alter the dose or stop taking the medication without consulting your healthcare provider. Consistent daily use is essential for maintaining optimal asthma control and preventing symptom exacerbations.
Adults and Adolescents (15 Years and Older)
Standard Dosage
The recommended dose is one 10 mg film-coated tablet taken once daily in the evening. The evening dosing schedule is based on clinical pharmacology studies demonstrating optimal airway protection overnight, when asthma symptoms typically worsen. Montelukast Viatris can be taken with or without food.
For patients using montelukast for both asthma and seasonal allergic rhinitis, a single 10 mg tablet in the evening covers both conditions. Do not take additional montelukast or any other product containing montelukast alongside this medication.
Elderly Patients
Elderly Dosage
No dosage adjustment is necessary for elderly patients. The standard dose of 10 mg once daily in the evening applies. Clinical studies have included patients aged 65 and older with no evidence of increased adverse effects or need for dose modification in this age group. Renal and hepatic function should be assessed as part of routine care.
Children and Adolescents Under 15 Years
Paediatric Formulations
Montelukast Viatris 10 mg film-coated tablets are not suitable for children or adolescents under 15 years of age. For paediatric patients, age-appropriate formulations are available: 5 mg chewable tablets for children aged 6–14 years and 4 mg chewable tablets or granules for children aged 2–5 years. Your paediatrician or respiratory specialist will determine the appropriate formulation and dose.
Missed Dose
If you forget to take your tablet, simply skip the missed dose and resume your regular schedule with one tablet the following evening. Do not take a double dose to make up for a missed one. Missing a single dose is unlikely to significantly affect your overall asthma control, but regular adherence is important for optimal treatment outcomes. Setting a daily reminder or incorporating the dose into your evening routine can help maintain consistency.
Overdose
If you take more Montelukast Viatris than prescribed, or if a child accidentally ingests the medication, contact your doctor, hospital emergency department, or poison control centre immediately. In the majority of reported overdose cases, no adverse effects were observed. The most commonly reported symptoms during montelukast overdose include abdominal pain, drowsiness, thirst, headache, vomiting, and psychomotor hyperactivity. There is no specific antidote for montelukast overdose; treatment is supportive and symptomatic.
| Patient Group | Dose | Formulation | Frequency |
|---|---|---|---|
| Adults & adolescents (≥15 years) | 10 mg | Film-coated tablet | Once daily in the evening |
| Children 6–14 years | 5 mg | Chewable tablet | Once daily in the evening |
| Children 2–5 years | 4 mg | Chewable tablet / Granules | Once daily in the evening |
| Elderly | 10 mg | Film-coated tablet | Once daily in the evening (no adjustment) |
Stopping Treatment
Montelukast Viatris is only effective if taken continuously as prescribed. Do not discontinue the medication without consulting your doctor, even if you feel well. Stopping treatment prematurely can lead to a gradual return of asthma symptoms and loss of disease control. If your doctor decides to stop montelukast, the transition should be managed carefully, potentially with adjustment of other asthma medications to maintain adequate control.
What Are the Side Effects of Montelukast Viatris?
Like all medicines, Montelukast Viatris can cause side effects, although not everybody gets them. The overall safety profile of montelukast has been established through extensive clinical trials and post-marketing surveillance spanning over two decades. Most side effects are mild and transient; however, certain serious adverse effects require immediate medical attention.
The side effects listed below are categorised by frequency according to international pharmacovigilance conventions. If you experience any side effect that concerns you, or if any effect becomes severe, contact your healthcare provider promptly.
Very Common
May affect more than 1 in 10 people
- Upper respiratory tract infection
Common
May affect up to 1 in 10 people
- Abdominal pain
- Headache
- Diarrhoea
- Nausea, vomiting
- Skin rash
- Fever (pyrexia)
- Elevated liver enzymes (ALT, AST)
Uncommon
May affect up to 1 in 100 people
- Allergic reactions (angioedema — swelling of face, lips, tongue, throat)
- Behavioural and mood changes: agitation, aggression, hostility, depression
- Abnormal dreams, nightmares, insomnia, sleepwalking
- Irritability, anxiety, restlessness
- Dizziness, drowsiness, paraesthesia (tingling/numbness)
- Nosebleed (epistaxis)
- Dry mouth, dyspepsia (indigestion)
- Bruising, pruritus (itching), urticaria (hives)
- Joint or muscle pain, muscle cramps
- Bedwetting (enuresis) in children
- Fatigue, malaise, oedema (swelling)
- Seizures
Rare
May affect up to 1 in 1,000 people
- Increased bleeding tendency
- Tremor
- Palpitations
- Attention disturbance, memory impairment
- Involuntary muscle movements (tics)
Very Rare
May affect up to 1 in 10,000 people
- Eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)
- Decreased platelet count (thrombocytopenia)
- Hallucinations, disorientation, suicidal thoughts and behaviour
- Pulmonary eosinophilia (lung inflammation)
- Erythema multiforme (severe skin reaction)
- Erythema nodosum (tender red nodules under the skin)
- Hepatitis (liver inflammation)
- Obsessive-compulsive symptoms, stuttering
Contact your doctor or seek emergency care immediately if you experience: severe allergic reactions (difficulty breathing, swelling of face/lips/throat), behavioural or mood changes (especially depression, suicidal thoughts), a combination of flu-like symptoms with tingling/numbness and worsening breathing (possible Churg–Strauss syndrome), or signs of severe skin reactions (widespread rash, blistering).
Neuropsychiatric Side Effects — Important Safety Information
Neuropsychiatric events are an important safety concern associated with montelukast use. These effects have been reported across all age groups and include mood changes, sleep disturbances, behavioural changes (agitation, aggression), depression, anxiety, and in rare cases, suicidal thinking and behaviour. The U.S. Food and Drug Administration (FDA) strengthened its warnings about these risks in 2020, adding a Boxed Warning to the montelukast prescribing information.
Healthcare providers, patients, and caregivers should be vigilant for any changes in behaviour or mood during montelukast therapy. It is especially important to monitor children and adolescents, who may be less able to articulate psychological symptoms. If neuropsychiatric symptoms develop, treatment should be re-evaluated and potentially discontinued. The EMA has also recommended that information about these risks be prominently displayed in the product information for all montelukast-containing medicines across Europe.
Reporting Side Effects
Reporting suspected adverse reactions after authorisation of a medicine is important. It allows continued monitoring of the benefit-risk balance of the medication. Healthcare professionals and patients are encouraged to report suspected side effects to their national pharmacovigilance authority. In the UK, reports can be made via the Yellow Card Scheme; in the US, via the FDA MedWatch programme; and in the EU, via the national competent authority.
How Should You Store Montelukast Viatris?
Proper storage of medications is important to maintain their effectiveness and safety throughout the shelf life. Montelukast Viatris does not require any special storage conditions, making it straightforward to store at home. Keep the tablets in the original packaging (blister or container) to protect them from moisture and light.
Keep out of the sight and reach of children. Store medications in a secure location, preferably a locked cabinet, to prevent accidental ingestion by children or pets. Montelukast overdose in children, while rarely serious, should still be treated as a medical emergency.
Expiry date: Do not use Montelukast Viatris after the expiry date stated on the carton, blister pack, or label after “EXP.” The expiry date refers to the last day of the stated month. Expired medications may have reduced potency and should be disposed of properly.
Disposal: Do not dispose of medicines via wastewater or household waste. Return unused or expired medications to your pharmacy for safe disposal. These measures help to protect the environment and prevent accidental exposure.
What Does Montelukast Viatris Contain?
Active Ingredient
Each Montelukast Viatris 10 mg film-coated tablet contains 10 mg of montelukast, present as montelukast sodium. Montelukast sodium is a hygroscopic, optically active white to off-white powder that is freely soluble in ethanol, methanol, and water. It has a molecular formula of C35H35ClNNaO3S and a molecular weight of approximately 608.2 g/mol.
Excipients (Inactive Ingredients)
Tablet core: Microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate, colloidal anhydrous silica.
Film-coating: Polydextrose, titanium dioxide (E171), hypromellose, triacetin, macrogol, indigo carmine aluminium lake (E132), para-orange aluminium lake (E110).
Appearance and Pack Sizes
Montelukast Viatris 10 mg tablets are blue, round, biconvex, film-coated tablets with a bevelled edge. They are marked “MO” over “10” on one side and “M” on the other side. The tablets are available in blister packs containing 10, 14, 20, 28, 30, 50, 56, 60, 84, 90, or 100 tablets; perforated unit-dose blisters containing 28×1 tablets; or containers with silica gel desiccant containing 28, 30, 56, 60, 84, 90, 100, 112, 120, 180, or 500 tablets. Not all pack sizes may be marketed in every country.
Marketing Authorisation Holder
Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, Ireland.
Frequently Asked Questions
Montelukast Viatris is a leukotriene receptor antagonist used for the prevention and long-term treatment of asthma in adults and adolescents aged 15 years and older. It works by blocking leukotrienes, which are chemicals that cause airway inflammation and constriction. It is also used to prevent exercise-induced bronchoconstriction and to treat seasonal allergic rhinitis (hay fever) in patients who have asthma. It is not a rescue medication and should not be used for acute asthma attacks.
Take one 10 mg tablet once daily in the evening. You can take it with or without food. It is important to continue taking the tablet every day, even when you feel well and have no symptoms. Do not take a double dose if you miss one — simply take your next dose at the regular time. Do not stop taking the medication without consulting your doctor.
Yes. Neuropsychiatric effects have been reported with montelukast, including agitation, aggression, anxiety, depression, sleep disturbances, hallucinations, and in rare cases suicidal thinking or behaviour. These effects can occur in patients of any age. The FDA has issued a Boxed Warning about these risks. If you or someone you know notices mood changes, unusual behaviour, or feelings of depression while taking montelukast, contact a healthcare provider immediately.
There is limited data on montelukast use in pregnancy. Animal studies have not shown harmful effects, but the decision to use montelukast during pregnancy should be made by your doctor, who will weigh the benefits of treating your asthma against potential risks. It is not known whether montelukast passes into breast milk in humans. Discuss with your doctor if you are breastfeeding or planning to breastfeed.
No, you should not stop taking montelukast without consulting your doctor, even if your symptoms improve. Asthma is a chronic condition that requires ongoing management. Montelukast works preventively, and stopping it can lead to a gradual return of symptoms and worsening asthma control. Your doctor will advise you on when and how to safely adjust or discontinue your medications based on your overall treatment plan.
Montelukast can interact with certain drugs. CYP3A4 inducers such as phenobarbital, phenytoin, and rifampicin can reduce montelukast levels and decrease its effectiveness. Gemfibrozil, a CYP2C8 inhibitor, can significantly increase montelukast levels. However, montelukast can generally be used safely alongside inhaled corticosteroids, beta-agonist inhalers, and antihistamines. Always tell your doctor about all medications you are taking.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Montelukast — Summary of Product Characteristics. European public assessment reports. Available at: ema.europa.eu.
- U.S. Food and Drug Administration (FDA). Singulair (montelukast sodium) — Prescribing Information and Boxed Warning (2020). Available at: fda.gov.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024 Report. Available at: ginasthma.org.
- British National Formulary (BNF). Montelukast. NICE Evidence Services. Available at: bnf.nice.org.uk.
- World Health Organization (WHO). Chronic respiratory diseases — Asthma. Fact Sheet. Available at: who.int.
- Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2012;(5):CD002314. doi:10.1002/14651858.CD002314.pub3.
- Philip G, et al. Montelukast for the treatment of exercise-induced bronchoconstriction in adults: a randomised, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 2009;123(4):735–743.
- Haarman MG, et al. Neuropsychiatric adverse drug reactions of montelukast: A systematic review. Pediatric Allergy and Immunology. 2022;33(9):e13835.
- Karonen T, et al. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognised role for CYP2C8 in the metabolism of montelukast. Clinical Pharmacology & Therapeutics. 2012;92(3):377–382.
Editorial Team & Medical Review
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians and clinical pharmacologists. Our content follows the GRADE evidence framework and adheres to guidelines from the WHO, EMA, FDA, GINA, and BNF.
iMedic Medical Editorial Team — Specialists in Respiratory Medicine and Clinical Pharmacology
iMedic Medical Review Board — Independent expert panel reviewing all content according to international guidelines
Level 1A — Based on systematic reviews and meta-analyses of randomised controlled trials
No commercial funding. No pharmaceutical company sponsorship. Independent medical editorial content.